Biogen Inc. (NASDAQ:BIIB) Files An 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers
Item5.02
|
Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. |
On June10, 2017, Paul Clancy notified Biogen Inc. (the Company)
that he will step down as Executive Vice President, Finance and
Chief Financial Officer of the Company to join another
biopharmaceutical company. Mr.Clancy will remain at the Company
through the second quarter of fiscal 2017 and will assist with
the transition.
On June10, 2017, the Company appointed Gregory F. Covino, the
Companys Vice President, Finance and Chief Accounting Officer, as
the Companys interim Principal Financial Officer, effective upon
Mr.Clancys departure. Mr.Covino will serve as the Companys
interim Principal Financial Officer as the Company conducts a
search for a new Chief Financial Officer.
Mr.Covino, age 51, has served as the Companys Vice President and
Chief Accounting Officer since April 2012. Prior to that,
Mr.Covino served at Boston Scientific Corporation, a medical
device company, as Vice President, Corporate Analysis and Control
Executive since March 2010, having responsibility for the
companys internal audit function, and as Vice President, Finance,
International from February 2008 to March 2010, having
responsibility for the financial activities of the companys
international division. Prior to that, Mr.Covino held several
finance positions at Hubbell Incorporated, an electrical products
company, including Vice President, Chief Accounting Officer and
Controller from 2002 to 2008, Interim Chief Financial Officer
from 2004 to 2005, and Director, Corporate Accounting from 1999
to 2002.
| Item7.01 | Regulation FD Disclosure. |
On June 13, 2017, the Company issued a press release announcing
that Mr. Clancy will step down as Executive Vice President,
Finance and Chief Financial Officer of the Company and the
appointment of Mr. Covino as the interim Principal Financial
Officer. A copy of the press release is furnished as Exhibit 99.1
and is incorporated herein by reference.
The press release being furnished in this Item 7.01 shall not be
deemed filed for purposes of Section 18 of the Securities
Exchange Act of 1934, as amended (the Exchange Act), or otherwise
subject to the liabilities of that Section, nor shall such
document be deemed incorporated by reference in any filing under
the Securities Act of 1933, as amended, or the Exchange Act.
| Item9.01 | Financial Statements and Exhibits. |
| (d) | Exhibits |
The exhibit listed on the Exhibit Index below is furnished as
part of this Current Report on Form 8-K.
2
About Biogen Inc. (NASDAQ:BIIB)
Biogen Inc., formerly Biogen Idec Inc., is a biopharmaceutical company. The Company operates in discovering, developing, manufacturing and delivering therapies to patients for the treatment of neurodegenerative diseases, hematologic conditions and autoimmune disorders segment. The Company markets products, including TECFIDERA, AVONEX, PLEGRIDY, TYSABRI and FAMPYRA for multiple sclerosis (MS), ELOCTATE for hemophilia A and ALPROLIX for hemophilia B, and FUMADERM for the treatment of severe plaque psoriasis. It also has a collaboration agreement with Genentech, Inc., a member of the Roche Group, with respect to RITUXAN for the treatment of non-Hodgkin’s lymphoma, chronic lymphocytic leukemia (CLL) and other conditions, GAZYVA indicated for the treatment of CLL and follicular lymphoma, and other potential anti-CD20 therapies. It also develops late stage product candidates, including Aducanumab (BIIB037) for the treatment of Neurodegeneration, and Nusinersen for other programs.
